Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $162.00

Sarepta Therapeutics (NASDAQ:SRPTGet Rating) had its target price upped by Needham & Company LLC from $150.00 to $162.00 in a research note issued to investors on Friday morning, The Fly reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other research firms have also commented on SRPT. Credit Suisse Group dropped their price target on Sarepta Therapeutics from $95.00 to $90.00 and set a neutral rating on the stock in a research report on Friday, June 24th. Cantor Fitzgerald decreased their price target on Sarepta Therapeutics from $140.00 to $128.00 and set an overweight rating for the company in a research note on Friday, June 24th. Morgan Stanley reduced their target price on Sarepta Therapeutics from $77.00 to $74.00 and set an equal weight rating for the company in a research note on Thursday, May 19th. The Goldman Sachs Group dropped their price target on Sarepta Therapeutics from $181.00 to $155.00 and set a buy rating for the company in a report on Tuesday, May 24th. Finally, StockNews.com cut Sarepta Therapeutics from a buy rating to a hold rating in a report on Saturday, May 21st. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of Moderate Buy and an average price target of $120.25.

Sarepta Therapeutics Trading Up 8.2 %

NASDAQ:SRPT opened at $92.95 on Friday. Sarepta Therapeutics has a 1-year low of $61.28 and a 1-year high of $101.24. The business’s 50-day moving average price is $75.54 and its two-hundred day moving average price is $75.66. The company has a current ratio of 5.56, a quick ratio of 5.13 and a debt-to-equity ratio of 1.28. The firm has a market capitalization of $8.13 billion, a price-to-earnings ratio of -21.92 and a beta of 1.22.

Sarepta Therapeutics (NASDAQ:SRPTGet Rating) last released its quarterly earnings results on Wednesday, May 4th. The biotechnology company reported ($1.20) EPS for the quarter, topping analysts’ consensus estimates of ($1.35) by $0.15. The company had revenue of $210.83 million for the quarter, compared to analyst estimates of $208.25 million. Sarepta Therapeutics had a negative return on equity of 52.06% and a negative net margin of 46.56%. Sarepta Therapeutics’s revenue was up 43.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($2.10) earnings per share. On average, equities analysts expect that Sarepta Therapeutics will post -4.54 earnings per share for the current year.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors have recently made changes to their positions in SRPT. Exchange Traded Concepts LLC grew its position in shares of Sarepta Therapeutics by 191.7% in the 2nd quarter. Exchange Traded Concepts LLC now owns 633 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 416 shares during the last quarter. IndexIQ Advisors LLC bought a new stake in shares of Sarepta Therapeutics in the 1st quarter valued at about $61,000. UMB Bank N A MO bought a new stake in shares of Sarepta Therapeutics in the 4th quarter valued at about $69,000. KRS Capital Management LLC bought a new stake in shares of Sarepta Therapeutics in the 4th quarter valued at about $96,000. Finally, Laurel Wealth Planning LLC bought a new stake in shares of Sarepta Therapeutics in the 1st quarter valued at about $117,000. Institutional investors own 81.43% of the company’s stock.

Sarepta Therapeutics Company Profile

(Get Rating)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.

Further Reading

The Fly logo

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Want More Great Investing Ideas?

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.